Xianzhao Yang
Overview
Explore the profile of Xianzhao Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Yang X, Tan L, Tian Y, Zhao Z, Ru S
Front Pharmacol
. 2024 Nov;
15:1474342.
PMID: 39545069
Objective: This meta-analysis aims to assess the efficacy and safety of adding pegylated interferon (Peg-IFN) to long-term nucleos(t)ide analogs (NAs) treatment for achieving functional cure in patients with chronic hepatitis...
2.
Li S, Li Z, Du H, Zao X, Gan D, Yang X, et al.
Front Public Health
. 2023 Apr;
11:1137738.
PMID: 37089512
Background And Aims: Patients with chronic hepatitis B (CHB) in the immune tolerant (IT) phase were previously thought to have no or slight inflammation or fibrosis in the liver. In...
3.
Cao X, Chen H, Li Z, Li X, Yang X, Jin Q, et al.
Front Pharmacol
. 2022 Sep;
13:985084.
PMID: 36133813
The Chinese traditional medicine KangXianYiAi formula (KXYA) is used to treat hepatic disease in the clinic. Here we aim to confirm the therapeutic effects and explore the pharmacological mechanisms of...
4.
Li X, Zhou D, Chi X, Li Q, Wang L, Lu B, et al.
Hepatol Int
. 2020 Oct;
14(6):985-996.
PMID: 33128206
Background And Aim: Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV)...
5.
Li X, Zhang L, Qiu M, Huang Y, Xiao H, Lu B, et al.
Trials
. 2020 Aug;
21(1):708.
PMID: 32787905
Background: Nucleos(t)ide analogues (NAs) are the first-line option against chronic hepatitis B (CHB). NAs produce potent suppression of viral replication with a small chance of HBsAg seroclearance and a high...
6.
Yang X, Ru S, Luo L, Lv X, Bai W, Zhang F, et al.
Trials
. 2019 Feb;
20(1):127.
PMID: 30760320
Background: Ascites is one of the most common complications of cirrhosis. Umbilical therapy with traditional Chinese medicines has been increasingly prescribed to treat cirrhotic ascites. However, high-quality evidence from clinical...
7.
Li Y, Wang L, Yang X, Ye Y, Tu P, Wang J
Biomed Chromatogr
. 2018 Jul;
32(11):e4337.
PMID: 30003566
Tubeimoside I (Tub) is a triterpenoid saponin isolated from Bolbostemma paniculatum[Maxim]Franquet. A sensitive and validated method was developed to determine Tub in rat plasma. This method combined the qualitative and...
8.
Zhang P, Ye Y, Yang X, Jiao Y
Evid Based Complement Alternat Med
. 2016 Sep;
2016:3560812.
PMID: 27651817
Background. In recent years, with the popularity of CHM, its hepatotoxicity has also been increasingly noticed. However, there are still veils on causative herbs and clinical characteristics. Aim. To systematically...
9.
Yang T, Li F, Yang X, Wu Z, Feng X, Wang Y, et al.
BMC Public Health
. 2008 Jul;
8:248.
PMID: 18644139
Background: Although evidence has shown high prevalence rates of tobacco use in the general urban populations in China, relatively little is known in its rural population. The purposes of this...